Table 1.
Demographic and baseline characteristics
Characteristic [statistic]a | ITT population |
CE population |
||
---|---|---|---|---|
Solithromycin 800/400 mg (N = 65) | Levofloxacin 750 mg (N = 67) | Solithromycin 800/400 mg (N = 55) | Levofloxacin 750 mg (N = 58) | |
Patients in each country [n (%)] | ||||
United States | 63 (96.9) | 63 (94.0) | 54 (98.2) | 54 (93.1) |
Canada | 2 (3.1) | 4 (6.0) | 1 (1.8) | 4 (6.9) |
Age (yr) | ||||
Mean ± SD | 56.0 ± 13.0 | 55.2 ± 14.1 | 56.5 ± 13.2 | 54.8 ± 14.4 |
Range | 25–87 | 18–79 | 25–87 | 18–79 |
≥65 [n (%)] | 19 (29.2) | 17 (25.4) | 16 (29.1) | 15 (25.9) |
Race [n (%)] | ||||
White | 55 (84.6) | 54 (80.6) | 45 (81.8) | 46 (79.3) |
Asian | 5 (7.7) | 6 (9.0) | 5 (9.1) | 5 (8.6) |
Black | 3 (4.6) | 6 (9.0) | 3 (5.5) | 6 (10.3) |
American Indian or Alaskan Native | 1 (1.5) | 0 (0.0) | 1 (1.8) | 0 (0.0) |
Native Hawaiian/other Pacific Islander | 1 (1.5) | 0 (0.0) | 1 (1.8) | 0 (0.0) |
Other | 0 (0.0) | 1 (1.5) | 0 (0.0) | 1 (1.7) |
Ethnicity [n (%)] | ||||
Non-Hispanic or Latino | 54 (83.1) | 56 (83.6) | 46 (83.6) | 48 (82.8) |
Hispanic or Latino | 11 (16.9) | 11 (16.4) | 9 (16.4) | 10 (17.2) |
Gender [n (%)] | ||||
Male | 28 (43.1) | 39 (58.2) | 25 (45.5) | 34 (58.6) |
Female | 37 (56.9) | 28 (41.8) | 30 (54.5) | 24 (41.4) |
BMIb (kg/m2) | ||||
Mean ± SD | 30.4 ± 7.5 | 28.6 ± 6.6 | 30.5 ± 7.3 | 27.9 ± 6.1 |
Range | 14.1, 64.5 | 15.5, 52.6 | 14.1, 64.5 | 15.5, 46.2 |
PORT score risk class [n (%)] | ||||
I (0–50) | 2 (3.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
II (51–70) | 47 (72.3) | 50 (74.6) | 39 (70.9) | 44 (75.9) |
III (71–90) | 12 (18.5) | 15 (22.4) | 12 (21.8) | 13 (22.4) |
IV (91–105) (IVa + IVb) | 4 (6.2) | 2 (3.0) | 4 (7.3) | 1 (1.7) |
IVa (91–98) | 3 (4.6) | 1 (1.5) | 3 (5.5) | 0 (0.0) |
IVb (99–105) | 1 (1.5) | 1 (1.5) | 1 (1.8) | 1 (1.7) |
Enrolled as a prior treatment failure [n (%)] | 6 (9.2) | 4 (6.0) | 6 (10.9) | 4 (6.9) |
n, number of patients with characteristic; N, number of patients in the specified population; %, 100 × (n/N).
BMI, body mass index.